3-(3-羧基)丙酰基甘草次酸|Carbenoxolone|cas:5697-56-3|西域试剂

3-(3-羧基)丙酰基甘草次酸,Carbenoxolone,分析标准品,HPLC≥99%

产品编号：Bellancom-YE29537| CAS NO：5697-56-3| MDL NO：MFCD00867458| 分子式：C₃₄H₅₀O₇| 分子量：570.76

Carbenoxolone 是甘草次酸的半合成衍生物，由于其抗炎特性，被广泛用于消化不良和消化性溃疡的治疗。Carbenoxolone，半通道和间隙连接蛋白抑制剂，具有治疗慢性肝病的治疗潜力。Carbenoxolone 抑制 Aβ42 聚集，是抗 AD 治疗潜力的合适候选者。Carbenoxolone 是小分子 Pannexin1 (Panx1，是一种 ATP 释放通道) 抑制剂，通过调节第一个细胞外环来减弱 Panx1 通道活性。 Carbenoxolone 是 11β-羟基类固醇脱氢酶1型 (11β-HSD1) 抑制剂，可将无活性的糖皮质激素转化为活性形式。 Carbenoxolone 具有抗 DENV 感染的抗病毒活性，靶点针对病毒本身。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-YE29537		￥1680.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

产品名称	3-(3-羧基)丙酰基甘草次酸
英文名称	Carbenoxolone
CAS编号	5697-56-3
产品描述	Carbenoxolone 是甘草次酸的半合成衍生物，由于其抗炎特性，被广泛用于消化不良和消化性溃疡的治疗。Carbenoxolone，半通道和间隙连接蛋白抑制剂，具有治疗慢性肝病的治疗潜力。Carbenoxolone 抑制 Aβ42 聚集，是抗 AD 治疗潜力的合适候选者。Carbenoxolone 是小分子 Pannexin1 (Panx1，是一种 ATP 释放通道) 抑制剂，通过调节第一个细胞外环来减弱 Panx1 通道活性。 Carbenoxolone 是 11β-羟基类固醇脱氢酶1型 (11β-HSD1) 抑制剂，可将无活性的糖皮质激素转化为活性形式。 Carbenoxolone 具有抗 DENV 感染的抗病毒活性，靶点针对病毒本身。
产品熔点	291-294 °C
产品沸点	687.4ºC at 760 mmHg
产品密度	1.20
产品闪点	211.6ºC
精确质量	570.35600
PSA	117.97000
LogP	6.82830
外观性状	白色结晶粉末
稳定性	常温常压下稳定，具有抗菌、抗肿瘤及肾上腺皮质激素样作用，可制成抗炎抗过敏制剂，用于治疗风湿性关节炎、气喘，甘草次酸是经典的抗炎药物，将其应用于化妆品中可调节皮肤的免疫功能，增强皮肤的抗病能力，消除炎症、预防过敏。
储存条件	避光，阴凉干燥处，密封保存

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品

危害码 (欧洲)	Xi
风险声明 (欧洲)	R36/37/38:Irritating to eyes, respiratory system and skin .
安全声明 (欧洲)	S26-S36-S37/39
WGK德国	3
海关编码	2938909030

Material Safety Data Sheet

Section1. Identiﬁcation of the substance
Product Name: Carbenoxolone
Synonyms:

Section2. Hazards identiﬁcation
Harmful by inhalation, in contact with skin, and if swallowed.

Section3. Composition/information on ingredients.
Ingredient name:Carbenoxolone
CAS number:5697-56-3

Section4. First aid measures
Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
ﬂushing of the eyes by separating the eyelids with ﬁngers. If irritation persists, seek medical
attention.
Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section5. Fire ﬁghting measures
In the event of a ﬁre involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution:Wear approved mask/respirator
Hand precaution:Wear suitable gloves/gauntlets
Skin protection:Wear suitable protective clothing
Eye protection:Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section7. Handling and storage
Handling:This product should be handled only by, or under the close supervision of, those properly qualiﬁed
in the handling and use of potentially hazardous chemicals, who should take into account the ﬁre,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section9. Physical and chemical properties
Appearance:Not speciﬁed
Boiling point:No data
No data
Melting point:
Flash point:No data
Density:No data
Molecular formula:C34H50O7
Molecular weight:570.8

Section10. Stability and reactivity
Conditions to avoid: Heat, ﬂames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section11. Toxicological information
No data.

Section12. Ecological information
No data.

Section13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section14. Transportation information
Non-harzardous for air and ground transportation.

Section15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

SECTION 16 - ADDITIONAL INFORMATION
N/A

[1]. Sharma S, et al. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone:Insight into mechanism of action. Neurochem Int. 2017 Sep;108:481-493.

[2]. Crespo Yanguas S, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3). pii: E817.

[3]. Hirata K, et al. Formulation of carbenoxolone for delivery to the skin. Int J Pharm. 2013 May 20;448(2):360-5.

[4]. Michalski K, et al. Carbenoxolone inhibits Pannexin1 channels through interactions in the first extracellular loop. J Gen Physiol. 2016 Feb;147(2):165-74.

[5]. Kim J, et al. Protective effect of carbenoxolone on ER stress-induced cell death in hypothalamic neurons. Biochem Biophys Res Commun. 2015 Dec 25;468(4):793-9.

[6]. Pu J, et al. Antiviral activity of Carbenoxolone disodium against dengue virus infection. J Med Virol. 2017 Apr;89(4):571-581

3-(3-羧基)丙酰基甘草次酸,Carbenoxolone,分析标准品,HPLC≥99%

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询